Patent intelligence · US
US 12404318
Combination HBV therapy
Combination HBV therapy
Patent details — US 12404318
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 2, 2025
- Expiration
- Aug 28, 2045
- Applicant
- Vir Biotechnology, Inc.
- Claims
- 16
- CPC classes
- A61K, A61K2039/505, A61K2039/545, A61K31/522
Quick answer
US 12404318 (Combination HBV therapy) is held by Vir Biotechnology, Inc.. Status: granted. Granted Sep 2, 2025. Expires Aug 28, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Vir Biotechnology, Inc.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K2039/505, A61K2039/545, A61K31/522, A61K31/675, A61K31/7105
More from Vir Biotechnology, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11628215
HIV vaccines comprising one or more population episensus antigens
granted -
US 11554168
HIV vaccines comprising one or more population episensus antigens
granted -
US 11479599
Antibodies against SARS-CoV-2 and methods of using the same
granted -
US 11168128
Antibodies against SARS-CoV-2 and methods of using the same
granted -
US 10894078
HIV vaccines comprising one or more population episensus antigens
granted
Frequently asked questions
What is US patent 12404318?
US 12404318 (Combination HBV therapy) is held by Vir Biotechnology, Inc.. Status: granted. Granted Sep 2, 2025. Expires Aug 28, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12404318?
Vir Biotechnology, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 12404318 expire?
Our index shows an expiration date of Aug 28, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.